XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Cash flows from operating activities:    
Net loss $ (10,445) $ (10,214)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation 691 1,258
Depreciation and amortization 91 95
Loss on disposal of fixed assets 0 3
Loss from equity method investment 100 0
Amortization/accretion on marketable securities (285) (426)
Changes in operating assets and liabilities:    
Prepaid and other current assets (352) (1,161)
Other assets 83 117
Accounts payable, accrued liabilities and other liabilities (2,193) (2,052)
Net cash used in operating activities (12,310) (12,380)
Cash flows from investing activities:    
Purchase of marketable securities (28,515) (60,836)
Sale of marketable securities 46,764 64,400
Investment in Impilo Therapeutics (100) 0
Net cash provided by investing activities 18,149 3,564
Cash flows from financing activities:    
Proceeds from exercise of options 0 155
Tax withholding payments on net share settlement equity awards (142) (85)
Net proceeds from issuance of common stock 32 297
Net cash (used in) provided by financing activities (110) 367
Effect of exchange rate changes on cash (29) (15)
Net increase (decrease) in cash and cash equivalents 5,700 (8,464)
Cash and cash equivalents at beginning of period 22,593 32,154
Cash and cash equivalents at end of period $ 28,293 $ 23,690